1 - 25 of 66 results for author:"Comoglio P.M." in Literature citations
Results Customize
› Repeat search in UniProtKB (23)
| The MET oncogene is a functional marker of a glioblastoma stem cell subtype. De Bacco F., Casanova E., Medico E., Pellegatta S., Orzan F., Albano R., Luraghi P., Reato G., D'Ambrosio A., Porrati P. et al. Cancer Res. 72:4537-4550(2012) · Mapped (22) |
| A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., Cora D., Di Nicolantonio F., Buscarino M., Petti C. et al. Cancer Discov 1:508-523(2011) · Mapped (8) |
| MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Migliore C., Martin V., Leoni V.P., Restivo A., Atzori L., Petrelli A., Isella C., Zorcolo L., Sarotto I., Casula G. et al. Clin. Cancer Res. 18:737-747(2012) · Mapped (23) |
| Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Hwang C.I., Matoso A., Corney D.C., Flesken-Nikitin A., Korner S., Wang W., Boccaccio C., Thorgeirsson S.S., Comoglio P.M., Hermeking H. et al. Proc. Natl. Acad. Sci. U.S.A. 108:14240-14245(2011) · Mapped (92) |
| A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Torti D., Sassi F., Galimi F., Gastaldi S., Perera T., Comoglio P.M., Trusolino L., Bertotti A. Int. J. Cancer 130:1357-1366(2012) · Mapped (22) |
| Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Gentile A., Lazzari L., Benvenuti S., Trusolino L., Comoglio P.M. Cancer Res. 71:3132-3141(2011) · Mapped (2) |
| Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Galimi F., Torti D., Sassi F., Isella C., Cora D., Gastaldi S., Ribero D., Muratore A., Massucco P., Siatis D. et al. Clin. Cancer Res. 17:3146-3156(2011) · Mapped (28) |
| Ron kinase transphosphorylation sustains MET oncogene addiction. Benvenuti S., Lazzari L., Arnesano A., Li Chiavi G., Gentile A., Comoglio P.M. Cancer Res. 71:1945-1955(2011) · Mapped (27) |
| MET mutations in cancers of unknown primary origin (CUPs). Stella G.M., Benvenuti S., Gramaglia D., Scarpa A., Tomezzoli A., Cassoni P., Senetta R., Venesio T., Pozzi E., Bardelli A. et al. |
| The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. Franco M., Muratori C., Corso S., Tenaglia E., Bertotti A., Capparuccia L., Trusolino L., Comoglio P.M., Tamagnone L. J. Biol. Chem. 285:38756-38764(2010) · Mapped (18) |
| Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. Casazza A., Finisguerra V., Capparuccia L., Camperi A., Swiercz J.M., Rizzolio S., Rolny C., Christensen C., Bertotti A., Sarotto I. et al. J. Clin. Invest. 120:2684-2698(2010) · Mapped (7) |
| MicroRNAs impair MET-mediated invasive growth. Migliore C., Petrelli A., Ghiso E., Corso S., Capparuccia L., Eramo A., Comoglio P.M., Giordano S. Cancer Res. 68:10128-10136(2008) · Mapped (22) |
| The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis. Stella M.C., Trusolino L., Comoglio P.M. Mol. Biol. Cell 20:642-657(2009) |
| Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis. Cassano M., Biressi S., Finan A., Benedetti L., Omes C., Boratto R., Martin F., Allegretti M., Broccoli V., Cusella De Angelis G. et al. PLoS ONE 3:e3223-e3223(2008) · Mapped (20) |
| Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. Sierra J.R., Corso S., Caione L., Cepero V., Conrotto P., Cignetti A., Piacibello W., Kumanogoh A., Kikutani H., Comoglio P.M. et al. J. Exp. Med. 205:1673-1685(2008) · Mapped (2) |
| Met-driven invasive growth involves transcriptional regulation of Arhgap12. Gentile A., D'Alessandro L., Lazzari L., Martinoglio B., Bertotti A., Mira A., Lanzetti L., Comoglio P.M., Medico E. Oncogene 27:5590-5598(2008) · Mapped (43) |
| A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. Basilico C., Arnesano A., Galluzzo M., Comoglio P.M., Michieli P. J. Biol. Chem. 283:21267-21277(2008) · Mapped (40) |
| The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. Rolny C., Capparuccia L., Casazza A., Mazzone M., Vallario A., Cignetti A., Medico E., Carmeliet P., Comoglio P.M., Tamagnone L. J. Exp. Med. 205:1155-1171(2008) · Mapped (7) |
| The Met tyrosine kinase receptor in development and cancer. Gentile A., Trusolino L., Comoglio P.M. Cancer Metastasis Rev. 27:85-94(2008) · Mapped (22) |
| Silencing the MET oncogene leads to regression of experimental tumors and metastases. Corso S., Migliore C., Ghiso E., De Rosa G., Comoglio P.M., Giordano S. Oncogene 27:684-693(2008) · Mapped (22) |
| Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesis. Fazzari P., Penachioni J., Gianola S., Rossi F., Eickholt B.J., Maina F., Alexopoulou L., Sottile A., Comoglio P.M., Flavell R.A. et al. BMC Dev. Biol. 7:55-55(2007) · Mapped (25) |
| A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Rasola A., Fassetta M., De Bacco F., D'Alessandro L., Gramaglia D., Di Renzo M.F., Comoglio P.M. Oncogene 26:1078-1087(2007) · Mapped (28) |
| Invasive growth: a MET-driven genetic programme for cancer and stem cells. Boccaccio C., Comoglio P.M. Nat. Rev. Cancer 6:637-645(2006) · UniProtKB (1) |
| Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Petrelli A., Circosta P., Granziero L., Mazzone M., Pisacane A., Fenoglio S., Comoglio P.M., Giordano S. Proc. Natl. Acad. Sci. U.S.A. 103:5090-5095(2006) · Mapped (22) |
| p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Coltella N., Rasola A., Nano E., Bardella C., Fassetta M., Filigheddu N., Graziani A., Comoglio P.M., Di Renzo M.F. Int. J. Cancer 118:2981-2990(2006) · Mapped (5) |